MDMA
MDMA
Systematic (IUPAC) name
1-(benzo[d][1,3]dioxol-5-yl)-N-
methylpropan-2-amine
Identifiers
CAS number
69610-10-2
ATC code
?
PubChem
1615
ChemSpider
1556
Chemical data
Formula
C11H15NO2
Mol. mass
193.25 g/mol
SMILES
eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism
Hepatic, CYP extensively in-
volved, especially CYP2D6
Half life
The half-life of MDMA is
dose dependent, increasing
with higher doses, but is
around 6–10 hours at doses
of 40–125 mg
Excretion
Renal
Therapeutic considerations
Pregnancy
cat.
C[1]
Legal status
Prohibited (S9)(AU) Sched-
ule III(CA) Class A(UK)
Schedule I(US)
Routes
Oral, Sublingual, Inhala-
tion, Injection[2]
MDMA
(3,4-methylenedioxymethamphetamine,
also known as Ecstasy) is a semisynthetic
member of the amphetamine class of psycho-
active drugs. It is considered unusual for its
tendency to produce a sense of intimacy with
others and diminished feelings of fear and
anxiety. These effects have led some to sug-
gest it might have therapeutic benefits to
some individuals. Before it was made a con-
trolled substance, MDMA was used to aid
psychotherapy, often couples therapy, the
results of which are poorly documented.
Studies have also recently been initiated to
examine the therapeutic potential of MDMA
for post-traumatic stress disorder and anxiety
associated with cancer.
MDMA is criminalized in most countries in
the world under a UN agreement,[3] and its
possession, manufacture, or sale may result
in criminal prosecution, although some lim-
ited exceptions exist for scientific and medic-
al research. MDMA is one of the most widely
used illicit drugs in the world[4] and is taken
in a variety of contexts far removed from its
roots in psychotherapeutic settings. It is com-
monly associated with the rave culture and
its related genres of music.
There have been debates within science,
health care, and drug policy circles about the
risks of MDMA, specifically the possibility of
neurotoxic damage to the central nervous
system. Regulatory authorities in several loc-
ati